Apart from ibrutinib, people with M-CLL, devoid of TP53 aberrations and healthy ample to tolerate FCR therapy, may still be good candidates for that latter, Together with the advantage being this treatment is often accomplished in 6 months when ibrutinib have to be taken indefinitely. This selection